Compounded · Dual GLP-1/GIP
Rated 4.9 by 127 RWell patients
Tirzepatide
Tirzepatide delivers clinical-grade weight loss — up to 20.9% of body weight — once a week, shipped to your door.
Starting at $116/mo
- Prescribed 100% online — no waiting rooms
- US-licensed clinicians
- Free 2-day shipping, discreetly packaged
- Transparent pricing with no hidden fees
Prescription products require an online consultation with a licensed clinician who will determine if a prescription is appropriate. Compounded medications are not FDA-approved or evaluated for safety, efficacy, or quality.
Use your HSA/FSANo Hidden Fees24/7 MessagingFree Expedited ShippingNo Membership Fees
How does Tirzepatide work?
- Tirzepatide works by mimicking two hormones — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).
- These hormones are naturally released after eating and help regulate appetite, slow stomach emptying, and control blood sugar levels.
Formulation
A once-weekly injection targeting both GLP-1 and GIP receptors for powerful, sustained results.
Enhanced with glycine
If indicated, your provider may prescribe a personalized formulation that includes glycine — a naturally occurring amino acid that supports collagen production, tissue repair, and muscle metabolism. Glycine has shown promise in preserving lean muscle during weight loss, reducing inflammation, and improving injection comfort.
4 easy steps to get started
- 1
Complete a short online intake
Answer a secure health questionnaire about your history and goals — about 5–10 minutes.
- 2
A licensed clinician reviews your intake
A clinician licensed in your state reviews your answers, typically in under 4 hours.
- 3
Compounded by a licensed pharmacy
If appropriate, your compounded prescription is sent to our partner compounding pharmacy.
- 4
Shipped discreetly to your door
Your medication ships free with 2-day service in plain, unbranded packaging.
Results that speak for themselves
Why choose RWell?
Simple, transparent pricing
No membership fees. No hidden charges. Auto-refills – cancel at least 48-hours prior to next refill.
Every RWell Plan Includes:
- No cost consultation
- Free UPS 2nd Day Air
- No membership or hidden fees
- Unlimited messaging with your care team
LegitScript Certified1 Month
$169
first order
Refills at $229
Auto-refills – cancel at least 48-hours prior to next refill
3 Months
Save 22%$179$116/mo
Limited-time offer
$349 total
Auto-refills – cancel at least 48-hours prior to next refill
🔥 First order for only $169, future refills at $229 (discount applies to starter dosage only)
☀️ Tirzepatide 3-month Starter Pack: Get Doses 2.5/5.0/7.5mg for $349, total. Use code: SUMMER
Dosing and safety
Treatment starts at a low dose and gradually increases over several weeks. Your provider will create a personalized dosing schedule based on your response and tolerance.
Possible side effects
- Nausea (usually temporary)
- Decreased appetite
- Diarrhea or constipation
- Injection site reactions
Rare but serious risks have been reported, including pancreatitis, gallbladder problems, and kidney injury. GLP-1s may cause serious side effects, including possible thyroid tumors, including cancer. See the 'Important Safety Information' links below for more details.
Explore other weight loss treatments
More energy. More life.
Show up for the moments that matter
More energy, more presence
End the food noise for good
No constant cravings
Clothes that actually fit again
Real, visible results
Patient reviews
What patients say
4.8290 reviews
Reviews are unedited patient feedback. Star ratings are an aggregate of individual ratings across three categories: medical care and provider interactions, customer service and communication, and delivery experience. Shown with initials only for privacy. Individual results vary and are not guaranteed.
Frequently asked questions
Tirzepatide is typically suitable for adults seeking substantial weight loss, especially if your BMI is over 27 with weight-related conditions or over 30. It's not recommended for people with a history of medullary thyroid cancer, pancreatitis or severe gastrointestinal disease.
Clinical trials show weight-loss averages of up to 20.9% over 72 weeks. Most users notice reduced appetite and cravings within the first few weeks, with steady weight loss thereafter. It's important to note that compounded medications should not be presumed equivalent to their branded counterparts, and they are not reviewed by the FDA for safety or effectiveness.
Tirzepatide is a dual agonist that targets both GLP-1 and GIP receptors, while semaglutide only targets GLP-1. This dual action often yields greater weight-loss results.
The most common side effects are GI-related – nausea, constipation, diarrhea, vomiting, and stomach discomfort – and they often improve over time. We start low and increase doses gradually to help minimize side effects. Rare but serious risks have been reported, including pancreatitis, gallbladder problems, and kidney injury. Tell your care team before surgery/anesthesia, since GLP-1s can slow gastric emptying.
Animal studies indicated a risk of thyroid C-cell tumors. The correlation to humans has not been established, but you should avoid GLP-1 medications if you or your family has a history of MTC or MEN2. Review Important Safety Information for full details.
Still have questions?
Get StartedReady to try Tirzepatide? (No lectures, we promise.)
If you've tried to lose weight before and it didn't work – we get it. That's exactly why we're here. Complete a quick eligibility check and a licensed provider will review your info.
Get Started*Clinical outcomes based on published tirzepatide trials, including SURMOUNT-1 (weight loss)¹, SURPASS-2 (glucose & metabolic health)², SURPASS-4 (cardiovascular outcomes)³, and SURMOUNT-OSA (sleep apnea)⁴. Compounded versions of Tirzepatide are not associated with Eli Lilly & Company and/or its genuine MOUNJARO® and/or ZEPBOUND® products. Compounded versions of Tirzepatide are not FDA approved, and neither the FDA nor any global regulatory agency has reviewed these products for safety, quality, or efficacy. GLP-1s may cause serious side effects, including possible thyroid tumors, including cancer. See the 'Safety Information' links below for more details.
Clinical References
1 Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.
2 Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515.
3 Del Prato, S., Kahn, S. E., Pavo, I., et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). The Lancet, 398(10313), 1811–1824.
4 Malhotra, A., Grunstein, R. R., Gao, L., et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine, 391(13), 1193–1205.
Compounded medications are prepared by licensed compounding pharmacies and are not FDA-approved. The FDA does not evaluate compounded medications for safety, efficacy, or quality. Prescription products require an online consultation with a licensed clinician who will determine if a prescription is appropriate. Individual results vary. This page is for informational purposes only and is not medical advice.